ABN AMRO Investment Solutions’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.16M Sell
120,817
-773,493
-86% -$42M 0.04% 245
2026
Q1
$56.1M Buy
894,310
+207,303
+30% +$16.6M 0.73% 33
2025
Q4
$65.5M Buy
687,007
+126,088
+22% +$12.4M 0.97% 23
2025
Q3
$54.8M Buy
560,919
+473,283
+540% +$49M 1.12% 22
2025
Q2
$9.41M Sell
87,636
-7,572
-8% -$766K 0.19% 95
2025
Q1
$9.6M Buy
95,208
+7,981
+9% +$804K 0.2% 96
2024
Q4
$7.79M Buy
87,227
+6,366
+8% +$560K 0.15% 104
2024
Q3
$6.78M Buy
80,861
+754
+0.9% +$59.4K 0.12% 125
2024
Q2
$6.17M Buy
80,107
+34,964
+77% +$2.56M 0.11% 135
2024
Q1
$3.09M Buy
45,143
+1,212
+3% +$77.9K 0.05% 218
2023
Q4
$2.54M Sell
43,931
-809
-2% -$43.2K 0.04% 239
2023
Q3
$2.36M Buy
44,740
+13,016
+41% +$683K 0.05% 240
2023
Q2
$1.72M Buy
31,724
+988
+3% +$51.6K 0.03% 253
2023
Q1
$1.54M Buy
+30,736
New +$1.45M 0.03% 270

Other funds holding BSX

ABN AMRO Investment Solutions's BSX Position: Q2 2026 in Review

ABN AMRO Investment Solutions reduced its Boston Scientific (BSX) stake by 86% in Q2 2026, selling an estimated $42M and leaving 120,817 shares worth $5.16M. The position accounts for 0.04% of the portfolio, ranked #245.

ABN AMRO Investment Solutions first reported a position in BSX in Q1 2023 and has held it in 14 quarters since. The position peaked at $65.5M in Q4 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • ABN AMRO Investment Solutions held 120,817 shares of Boston Scientific worth $5.16M as of Q2 2026.
  • ABN AMRO Investment Solutions sold 773,493 Boston Scientific shares in Q2 2026, an estimated $42M.
  • Boston Scientific made up 0.04% of ABN AMRO Investment Solutions's portfolio in Q2 2026, its #245 holding.
  • ABN AMRO Investment Solutions first reported a position in Boston Scientific in Q1 2023 and has held it in 14 quarters since.
  • ABN AMRO Investment Solutions's Boston Scientific position peaked at $65.5M in Q4 2025.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on ABN AMRO Investment Solutions's 13F filing for Q2 2026, filed 23 Jul 2026.